Bupropion/dextromethorphan - Axsome Therapeutics

Drug Profile

Bupropion/dextromethorphan - Axsome Therapeutics

Alternative Names: AXS-05

Latest Information Update: 11 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Developer Axsome Therapeutics; Duke University
  • Class Antidepressants; Morphinans; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic receptor antagonists; Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Depressive disorders
  • Phase II/III Agitation
  • Phase II Major depressive disorder; Smoking withdrawal

Most Recent Events

  • 05 Jun 2018 Phase-II clinical trials in Major depressive disorder in Unknown location (PO)
  • 25 Mar 2018 Phase-II clinical trials in Smoking withdrawal in USA (PO) (NCT03471767)
  • 23 Mar 2018 Axsome Therapeutics plans a phase II trial for Smoking withdrawal in USA in March 2018 , (NCT03471767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top